ENTEROBIOTIX LIMITED

SC559230
Active United Kingdom

Research and experimental development on biotechnology

65 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
E

ENTEROBIOTIX LIMITED

SC559230

Research and experimental development on biotechnology

Founded 2 Mar 2017 Active United Kingdom 65 employees website.com
Life sciences and medical technology Research and experimental development on biotechnology
Accounts Submitted 11 Sept 2025 Next due 30 Sept 2026 3 months remaining
Confirmation Submitted 4 Jun 2026 Next due 3 May 2027 10 months remaining
Net assets £-6M £8M 2023 year on year
Total assets £12M £2M 2023 year on year
Total Liabilities £18M £5M 2023 year on year
Charges None No charges registered

Contact & Details

Contact

Website

www.example.com

Full company profile for ENTEROBIOTIX LIMITED (SC559230), an active life sciences and medical technology company based in United Kingdom. Incorporated 2 Mar 2017. Research and experimental development on biotechnology. View financials, directors, shareholders, and filings.

Business Summary

This company specializes in providing innovative solutions and services across multiple sectors.

Products & Services

consulting software analytics integration

Reports

Credit Report

In-depth credit score, financial analysis, risk assessment and company intelligence.

Financials

Financials

Period 1 Jan → 31 Dec 2023
Type full
Next accounts 31 Dec 2025
Due by 30 Sept 2026 3 months remaining

Net Assets, Total Assets & Total Liabilities (2017–2023)

Cash in Bank

£7.36M

Decreased by £1.34M (-15%)

Net Assets

-£6.02M

Decreased by £7.66M (-467%)

Total Liabilities

£18.22M

Increased by £5.34M (+41%)

Turnover

N/A

Employees

65

Increased by 16 (+33%)

Debt Ratio

149%

Increased by 60 (+67%)

Financial History

Revenue, profit, EBITDA and key financial figures

2023
31 Dec Year End
2022
31 Dec Year End
P&L
Revenue
£142.3M
£128.7M
Gross Profit
£48.2M
£43.1M
Operating Profit
£22.4M
£19.8M
Net Profit
£18.1M
£15.9M
EBITDA
£31.5M
£28.2M
Assets
Cash
£24.7M
£21.3M
Total Assets
£89.4M
£82.1M
Liabilities
Total Liabilities
£45.2M
£41.8M
Key Metrics
Employees
1,247
1,156
Latest Revenue
£142.3M
Latest EBITDA
£31.5M
Cash Position
£24.7M

Funding

Fundraising & Grants

Funding Rounds 5
Grants 1

Investors (7)

Investor NameInvestor SinceParticipating Rounds
Investor 6Jan 2019Series A, Seed
Investor 2Sept 2021Venture - Series Unknown, Series B, Series A
Investor 3Sept 2021Venture - Series Unknown, Series B, Series A

Share Capital

Share Capital

Share allotments and capital structure

8 Allotments 2,733,615 Shares £629886.94m Total
Date FromShare ClassShares AllottedAmount RaisedPrice/Share
19 Jan 2024280,931£629878.25m£2.24m
9 Aug 2023771,511£6.16m£7.981
30 Dec 20191,235,512£1k£0.001
23 May 201950,333£301k£5.98
15 Mar 201979,257£474k£5.98

Officers

Officers

0 active 3 resigned
Status

No officers found

No officers found

Shareholders

Shareholders (122)

Trustee Of The Thairm Bio Nominee Trust B
31.2%
Trustee Of The Thairm Bio Nominee Trust A
12.8%

Persons with Significant Control

Persons with Significant Control (4)

4 Active 1 Ceased

Mark Bamforth

British,american

Active
Notified 10 Jan 2020
Residence United States
DOB January 1963
Nature of Control
  • Ownership Of Shares 25 To 50 Percent,voting Rights 25 To 50 Percent,right To Appoint And Remove Directors

Morag Bamforth

American

Active
Notified 21 Jan 2020
Residence United States
DOB April 1963
Nature of Control
  • Significant Influence Or Control

Mr Mark Bamforth

British,american

Active
Notified 10 Jan 2020
Residence United States
DOB January 1963
Nature of Control
  • Ownership Of Shares 25 To 50 Percent
  • Voting Rights 25 To 50 Percent
  • Right To Appoint And Remove Directors

Morag Bamforth

American

Active
Notified 21 Jan 2020
Residence United States
DOB April 1963
Nature of Control
  • Significant Influence Or Control

James Roger Mcilroy

Ceased 10 Jan 2020

Ceased

Group Structure

Group Structure

No group structure identified

Charges

Charges

No charges registered

Properties

Properties

0 total

No related properties

Documents

Company Filings

DateCategoryDescriptionDocument
4 Jun 2026Confirmation StatementConfirmation statement made on 19 Apr 2026 with updates
22 Apr 2026OfficersAppointment of Melissa Strange as director on 20 Apr 2026
16 Apr 2026CapitalAllotment of shares (GBP 9,299.202) on 30 Mar 2026
2 Apr 2026ResolutionResolutions
2 Apr 2026IncorporationMemorandum Articles
4 Jun 2026 Confirmation Statement

Confirmation statement made on 19 Apr 2026 with updates

22 Apr 2026 Officers

Appointment of Melissa Strange as director on 20 Apr 2026

16 Apr 2026 Capital

Allotment of shares (GBP 9,299.202) on 30 Mar 2026

2 Apr 2026 Resolution

Resolutions

2 Apr 2026 Incorporation

Memorandum Articles

Recent Activity

Latest Activity

Confirmation statement made on 19 Apr 2026 with updates

3 weeks ago on 4 Jun 2026

Appointment of Melissa Strange as director on 20 Apr 2026

2 months ago on 22 Apr 2026

Allotment of shares (GBP 9,299.202) on 30 Mar 2026

2 months ago on 16 Apr 2026

Resolutions

2 months ago on 2 Apr 2026

Memorandum Articles

2 months ago on 2 Apr 2026